Effect of metabolic blockade on the psychoactive effects of dextromethorphan

Human Psychopharmacology

Volumn 25, Issue 1, 2010, Pages 71-79

  Zawertailo, Laurie A ^a,b   Tyndale, Rachel F ^a,b   Busto, U ^a,b   Sellers, Edward M ^b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

CYP2D6; Dextromethorphan; Metabolism; Psychoactive effects; Quinidine

Indexed keywords

CYTOCHROME P450 2D6; DEXTROMETHORPHAN; DEXTRORPHAN; QUINIDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; EUPHORIA; FEMALE; GENE MUTATION; HUMAN; MALE; METABOLIC DISORDER; NORMAL HUMAN; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PAIN MEASUREMENT; QUINIDINE; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 76149093843     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1086     Document Type: Article

References (48)

1. Akerele E, Bisaga A, Sullivan MA, et al. 2008. Dextromethorphan and quinidine combination for heroin detoxification. Am J Addict 17: 176-180.
2. Alvan G, Bertilsson L, Dahl M-L, Ingelman-sundberg M, Sjoqvist F. Moving toward genetic profiling in patient care: the scope and rationale of pharmacogenetic/ecogenetic investigation. Drug Metab Disp 2001; 29(4): 580-585.
3. Baker SD, Borys DJ. 2002. A possible trend suggesting increased abuse from Coricidin exposures reported to the Texas Poison Network: comparing 1998 to 1999. Vet Hum Toxicol 44: 169-171.
4. Banerji S, Anderson IB. 2001. Abuse of Coricidin HBP cough & cold tablets: episodes recorded by a poison center. Am J Health Syst Pharm 58: 1811-1814.
5. Bem JL, Peck R. 1992. Dextromethorphan. An overview of safety issues. Drug Saf 7: 190-199.
6. Bertilsson L, Meese CO, Yue QY, et al. 1993. Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes. Pharmacogenetics 3: 94-100.
7. Bisaga A, Gianelli P, Popik P. 1997. Opiate withdrawal with dextromethorphan. Am J Psychiatry 154: 584.
8. Bisaga A, Popik P. 2000. In search of a new pharmacological treatment for drug and alcohol addiction: N-methyl-D-aspartate (NMDA) antagonists. Drug Alcohol Depend 59: 1-115.
9. Blin O, Azulay JP, Desnuelle C, et al. 1996. A controlled one-year trial of dextromethorphan in amyotrophic lateral sclerosis. Clin Neuropharmacol 19: 189-192.
10. Carlsson KC, Hoem NO, Moberg ER, Mathisen LC. 2004. Analgesic effect of dextromethorphan in neuropathic pain. Acta Anaesthesiol Scand 48: 328-336.
11. Carr BC. 2006. Efficacy, abuse, and toxicity of over-the-counter cough and cold medicines in the pediatric population. Curr Opin Pediatr 18: 184-188.
12. Chen ZR, Irvine RJ, Somogyi AA, Bochner F. 1991. μ receptor binding of some commonly used opioids and their metabolites. Life Sci 48: 2165-2171.
13. Cole JO, Orzack MH, Beake B, Bird M, Bar-Tal Y. 1982. Assessment of the abuse liability of buspirone in recreational sedative users. J Clin Psychiatry 43: 69-75.
14. Craig DF. 1992. Psychosis with Vicks formula 44-D abuse. CMAJ 146: 1199-1200.
15. Dayer P, Desmeules J, Leemann T, Striberni R. 1988. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). Biochem Biophys Res Commun 152: 411-416.
16. Desmeules J, Gascon MP, Dayer P, Magistris M. 1991. Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol 41: 23-26.
17. Dring LG, Smith RL, Williams RT. 1970. The metabolic fate of amphetamine in man and other species. Biochem J 116: 425-435.
18. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA. 1991. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 48: 943-950.
19. Grace AA, Camm AJ. 1998. Quinidine. N Engl J Med 338: 35-45.
20. Hildebrand M, Seifert W, Reichenberger A. 1989. Determination of dextromethorphan metabolizer phenotype in healthy volunteers. Eur J Clin Pharmacol 36: 315-318.
21. Hollander D, Pradas J, Kaplan R, McLeod HL, Evans WE, Munsat TL. 1994. High-dose dextromethorphan in amyotrophic lateral sclerosis: phase I safety and pharmacokinetic studies. Ann Neurol 36: 920-924.
22. Jacqz-Aigrain E, Funck-Brentano C, Cresteil T. 1993. CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 3: 197-204.
23. Jasinski DR. 2000. Abuse potential of morphine/dextromethorphan combinations. J Pain Symptom Manage 19: S26-30.
24. Jasinski DR, Mansky PA. 1972. Evaluation of nalbuphine for abuse potential. Clin Pharmacol Ther 13: 78-90.
25. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA. 1990. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem 265: 17209-17214.
26. Kaplan HL, Busto UE, Baylon GJ, et al. 1997. Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability. J Pharmacol Exp Ther 281: 103-108.
27. Kauppila T, Gronroos M, Pertovaara A. 1995. An attempt to attenuate experimental pain in humans by dextromethorphan, an NMDA receptor antagonist. Pharmacol Biochem Behav 52: 641-644.
28. Kitchen I, Tremblay J, Andre J, et al. 1979. Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamine. Xenobiotica 9: 397-404.
29. Koyuncuoglu H, Gungor M, Sagduyu H, Aricioglu F. 1990. Suppression by ketamine and dextromethorphan of precipitated abstinence syndrome in rats. Pharmacol Biochem Behav 35: 829-832.
30. Koyuncuoglu H, Saydam B. 1990. The treatment of heroin addicts with dextromethorphan: a double-blind comparison of dextromethorphan with chlorpromazine. Int J Clin Pharmacol Ther Toxicol 28: 147-152.
31. Levine DA. 2007. "Pharming": the abuse of prescription and over-the-counter drugs in teens. Curr Opin Pediatr 19: 270-274.
32. Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN. 1999. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol 56: 1383-1386.
33. Miksys S, Rao Y, Hoffmann E, Mash DC, Tyndale RF. 2002. Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics. J Neurochem 82: 1376-1387.
34. Montastruc JL, Fabre N, Rascol O, Senard JM, Blin O. 1994. N-methyl-Daspartate (NMDA) antagonist and Parkinson's disease: a pilot study with dextromethorphan. Mov Disord 9: 242-243.
35. Otton SV, Inaba T, Kalow W. 1984. Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs. Life Sci 34: 73-80.
36. Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM. 1993a. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther 54: 463-472.
37. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. 1993b. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 53: 401-409.
38. Parsons CG, Quack G, Bresink I, et al. 1995. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 34: 1239-1258.
39. Schadel M,Wu D, Otton SV, KalowW, Sellers EM. 1995. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. J Clin Psychopharmacol 15: 263-269.
40. Schmid B, Bircher J, Preisig R, Kupfer A. 1985. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 38: 618-624.
41. Sindrup SH, Hofmann U, Asmussen J, et al. 1996. Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. Eur J Clin Pharmacol 49: 503-509.
42. Soyka M, Bondy B, Eisenburg B, Schutz CG. 2000. NMDA receptor challenge with dextromethorphan-subjective response, neuroendocrinological findings and possible clinical implications. J Neural Transm 107: 701-714.
43. Wang JS, DeVane CL. 2003. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab Dispos 31: 742-747.
44. Wang Y, Unadkat JD. 1999. Enzymes in addition to CYP3A4 and 3A5 mediate N-demethylation of dextromethorphan in human liver microsomes. Biopharm Drug Dispos 20: 341-346.
45. Weinbroum AA, Gorodetzky A, Nirkin A, et al. Dextromethorphan for the reduction of immediate and late postoperative pain and morphine consumption in orthopedic oncology patients: a randomized, placebo-controlled, double-blind study. Cancer 95: 1164-1170.
46. Wolfe TR, Caravati EM. 1995. Massive dextromethorphan ingestion and abuse. Am J Emerg Med 13: 174-176.
47. Zawertailo LA, Busto U, Kaplan HL, Sellers EM. 1995. Comparative abuse liability of sertraline, alprazolam, and dextroamphetamine in humans. J Clin Psychopharmacol 15: 117-124.
48. Zawertailo LA, Kaplan HL, Busto UE, Tyndale RF, Sellers EM. 1998. Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study. J Clin Psychopharmacol 18: 332-337.